VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that, in its March 17, 2023 issue, Medical Xpress, has published an article titled “Study…

Source

Previous articleNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
Next articleatai Life Sciences Announces Key Clinical Pipeline and Corporate Updates